Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LITAF | Q99732 | 1/20 | 0.35 |
| ▸ | HPD | P32754 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26280725 | 0.91 | TNF (0.35) | TNFLITAFHPDMAPTMEN1 | |
| SCHEMBL24130132 | 0.87 | MAPT (0.35) | TNFLITAFHPDMAPTMEN1 | |
| SCHEMBL26280370 | 0.87 | MAPT (0.34) | MAPT | |
| SCHEMBL26280613 | 0.85 | MAPT (0.39) | MAPTMEN1HPGDBLMPMP22 | |
| SCHEMBL26280755 | 0.85 | MEN1 (0.32) | MAPTMEN1HPGDBLMPMP22 | |
| SCHEMBL26280865 | 0.84 | MAPT (0.40) | HPDMAPTHPGDKMT2AKDM4E | |
| SCHEMBL26280704 | 0.82 | MAPT (0.38) | MAPTMEN1HPGDBLMPMP22 | |
| SCHEMBL26280634 | 0.81 | MAPT (0.41) | HPDMAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL26280805 | 0.80 | EEF2K (0.40) | TNFLITAFHPDPDE4B | |
| SCHEMBL24130530 | 0.78 | MAPT (0.35) | TNFLITAFHPDMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | CBR3, DBF4, DDT | TNF 4793/4885LITAF 2991/4885HPD 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.